A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024 DOI Creative Commons
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu,

Leszek Wojnowski

и другие.

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Март 31, 2025

Abstract The US Food and Drug Administration approved 50 new drugs nine cellular gene therapy products in 2024, i.e., a total of 59 medical therapies. latter group represented three treatments each for oncology hematology/immunotherapy, one neurology, genetic disorders, cardiovascular disorders. Oncology, neurological disorders (14, six, seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe greater share first-in-class medications, more fast-track approvals, mRNA/gene/cell-based While small molecules remain largest fraction, their percentage has been declining substantially years. Taking together, these findings testify to commitment pharmaceutical industry innovative treatments, including conditions which no therapies existed. On other hand, there is trend approvals narrowly focused such as tumors defined by alterations.

Язык: Английский

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024 DOI Creative Commons
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu,

Leszek Wojnowski

и другие.

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Март 31, 2025

Abstract The US Food and Drug Administration approved 50 new drugs nine cellular gene therapy products in 2024, i.e., a total of 59 medical therapies. latter group represented three treatments each for oncology hematology/immunotherapy, one neurology, genetic disorders, cardiovascular disorders. Oncology, neurological disorders (14, six, seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe greater share first-in-class medications, more fast-track approvals, mRNA/gene/cell-based While small molecules remain largest fraction, their percentage has been declining substantially years. Taking together, these findings testify to commitment pharmaceutical industry innovative treatments, including conditions which no therapies existed. On other hand, there is trend approvals narrowly focused such as tumors defined by alterations.

Язык: Английский

Процитировано

0